Nov. 19, 2020: Metformin's effect on weight and gut microbiota; integrase and cardiometabolics in women with HIV; ongoing link between HIV, smoking, and cancer; how early HIV treatment initiation impacts future cervical cancer outcomes.
Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.
Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.
Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
However, the findings need to be studied in larger, more diverse populations.
May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.
April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.